Testing stopping treatment after asciminib for CML relapse
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older, and be able to sign informed consent
- Have chronic-phase CML (not a faster/blast form) and the usual BCR-ABL gene pattern (p210 form)
- Have tried stopping a CML tablet once before, and then had your disease return (“relapse”) after that stop
- Be on your same CML tablet now, but plan to stay on it or switch to asciminib for at least 12 months during the consolidation phase
- Have strong recent lab response: very low BCR-ABL on required central lab blood tests
- Not have had prior asciminib treatment, major blood count problems, serious pancreas episodes recently, or other key exclusions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
This study looks at whether people with chronic myeloid leukemia (CML) can safely lower their dose of targeted therapy before completely stopping it. It aims to see if a gradual reduction helps maintain long-term remission without the cancer coming back.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This study looks at stopping TKI treatment (a type of targeted therapy for CML) to see if you can stay in remission without medication. It is for people with CML in chronic phase who are either newly diagnosed or on a TKI but not achieving optimal results or not tolerating the drug.
Hear when a new Chronic Phase Chronic Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.